HCW Biologics Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance sheets

Condensed Balance Sheets

	December 31,	September 30,
	2023	2024
Unaudited
ASSETS
Current assets:
Cash and cash equivalents	$3,595,101	$998,221
Accounts receivable, net	1,535,757	651,840
Prepaid expenses	1,042,413	356,156
Other current assets	230,916	88,131
Total current assets	6,404,187	2,094,348
Investments	1,599,751	1,599,751
Property, plant and equipment, net	20,453,184	22,833,904
Other assets	56,538	28,476
Total assets	$28,513,660	$26,556,479
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Liabilities
Current liabilities:
Accounts payable	$6,167,223	$22,666,107
Accrued liabilities and other current liabilities	2,580,402	1,056,716
Short-term debt, net	—	6,340,511
Total current liabilities	8,747,625	30,063,334
Debt, net	6,304,318	6,462,769
Total liabilities	15,051,943	36,526,103
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 36,025,104 shares issued at December 31, 2023; 250,000,000 shares authorized and 37,823,394 shares issued at September 30, 2024	3,603	3,782
Additional paid-in capital	83,990,437	87,209,457
Accumulated deficit	(70,532,323)	(97,182,863)
Total stockholders’ equity (deficit)	13,461,717	(9,969,624)
Total liabilities and stockholders’ equity (deficit)	$28,513,660	$26,556,479

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.